Objective: To investigate the effect of preperative intravitreal ranibizumab(IVR) on vitrectomy and postoperative visual acuity in treatment of proliferative diabetic retinopathy(PDR). Methods: A retrospective analysis was performed on 90 eyes of 80 patients with PDR treated by 25G minimally invasive VRS. Patients were divided into observation group and control group according to the preoperative intravitreal injection of IVR. Observation group(39 cases,44 eyes) were treated with minimally invasive VRS (25G) after IVR injection, while the control group(41 cases, 46 eyes) were treated with minimally invasive VRS (25G)only.Postoperative follow up for 6 to 18 months, the operation process and postoperative visual acuity of the two groups were compared.Results: Compared with the control group, the operation time was significantly shorter (t=7.071,P<0.001),ntraocular electrocoagulation was decreased (t=2.395,P=0.019)in the observation group,the incidence rate of iatrogenic retinal hole (χ2=5.394,P=0.020), vitreous hemorrhage(χ2=6.429,P=0.011) and the fill rate of silicone oil (χ2=7.474,P=0.006) were lower. Six months after operation, there was no significant difference in logMAR BCVA between the two groups,but the logMAR BCVA was significantly higher than that before operation. Conclusion: Preoperative intravitrealIVR injection in the patients with PDR can obviously shorten the operation time of 25G minimally invasive VRS, reduce the fill rate of silicone oil and intraoperative bleeding, the incidence of iatrogenic retinal and vitreous body hematocele.It does not affect the postoperative visual acuity. |
[1] 蔡玲,崔建怡.严重增殖性糖尿病视网膜病变玻璃体切除术后视功能评价[J].国际眼科杂志,2016,16(4):633-637.
[2] 禹海,李鹤一,王颖,等.雷珠单抗玻璃体注射与玻璃体切除术治疗增殖性糖尿病视网膜病变[J].中国实用眼科杂志,2014,32(11):1301-1305.
[3] 李松涛,霍永军.Ⅵ期PDR患者术前应用雷珠单抗对玻璃体切割手术效果的影响[J].中国实用眼科杂志,2016,34(4):337-341.
[4] PAKZAD-VAEZI K,ALBIANI D A,KIRKER A W,et al.A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy[J].Ophthalmic Surg Lasers Imaging Retina,2014,45(6):521-524.
[5] BHAVSAR A R,TORRES K,GLASSMAN A R,et al.Evaluation of results one year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy[J].JAMA Ophthalmol,2014,132(7):889-890.
[6] HAN S Y,BAE J H,OH J,et al.Intravitreal ranibizumab for subfoveal choroidal neovascularization from age-related macular degeneration with combined severe diabetic retinopathy[J].Diabetes Metab J,2015,39(1):46-50.
[7] 付浴东,王萍,江莉,等.玻璃体腔注射雷珠单抗、全视网膜激光光凝对增生型糖尿病视网膜病变患眼玻璃体切割手术及治疗效果的影响[J].中华眼底病杂志,2015,31(2):143-146.
[8] 王丽,段文黎.两种光凝术治疗糖尿病视网膜病变的非随机对照研究[J].国际眼科杂志,2016,16(3):496-498.
[9] 王默,廖欣,谢春蕾,等.不同时间玻璃体腔注射雷珠单抗辅助玻璃体切割手术治疗增生型糖尿病视网膜病变的疗效观察[J].中华眼底病杂志,2016,32(3):300-305.
[10] IP M S,DOMALPALLY A,SUN J K,et al.Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy[J].Ophthalmology,2015,122(2):367-374.
[11] MESSIAS A,RAMOS FILHO J A,MESSIAS K,et al.Electroretinographic findings associated with panretinal photocoagulation(PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy[J].Doc Ophthalmol,2012,124(3):225-236.
[12] FERRAZ D A,VASQUEZ L M,PRETI R C,et al.A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy[J].Retina,2015,35(2):280-287.
[13] 郭翠玲,赵仲平,何琼敏,等.雷珠单抗玻璃体腔注射对增生性糖尿病视网膜病变患者血清血管内皮生长因子的影响[J].医学综述,2016,22(10):1984-1987.
[14] SASSA Y,YOSHIDA S,ISHIKAWA K,et al.The kinetics of VEGF and MCP-1 in the second vitrectomy cases with proliferative diabetic retinopathy[J].Eye(Lond),2016,30(5):746-753. |